Myriad Genetics (MYGN) Reports In-Line Q2 EPS, misses on revenue, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $5.82 +1.04%
Financial Fact:
Research and development expense: 19.4M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Research and development expense: 19.4M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $183.5 million versus the consensus estimate of $187.07 million.
GUIDANCE:
Myriad Genetics sees FY2023 EPS of ($0.36)-($0.24). Myriad Genetics sees FY2023 revenue of $730-750 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Investing.com’s stocks of the week
- Meta's capital-raising plans expose a major weakness in the AI boom
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
